TTNP News Alert Titan Pharma Inc (TTNP) 0.4800 12/25/2014 23

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Titan Pharma Inc (TTNP) 0.4800 $TTNP

First patient enrolled in Acorda Phase 3 PD trial
Seeking Alpha - at Seeking Alpha - Wed Dec 10, 7:06AM CST

IPXL: 31.32 (+0.26), ADMS: 16.10 (+1.45), TEVA: 57.09 (+0.33), ACOR: 39.14 (+0.74), PRTA: 20.14 (+1.41), NDRM: 5.90 (-0.19)

Titan Pharmaceuticals to Present at LD Micro Conference
Marketwired - Mon Dec 01, 6:00AM CST
Titan Pharmaceuticals, Inc. (OTCBB: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura(TM) long-term drug delivery technology, announced today that its President, Sunil Bhonsle, will present at the 7th annual LD Micro "Main Event" Micro-Cap Growth Conference on Thursday, Dec. 4 at 8:30 a.m. PT. The conference will be held at the Luxe Sunset Bel Air Hotel, in Los Angeles, Calif.

Enrollment complete in Probuphine Phase 3
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 9:03AM CST


Titan Pharmaceuticals Announces Completion of Enrollment in Phase 3 Study of Probuphine for Opioid Dependence
Marketwired - Thu Nov 20, 5:01AM CST
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced completion of enrollment in the ongoing Phase 3 study of Probuphine(R), the company's investigational subdermal implant for the maintenance treatment of opioid dependence. Study completion is expected to be on schedule by the middle of 2015, paving the way for resubmission of the New Drug Application (NDA) for Probuphine with the U.S. Food and Drug Administration (FDA) later in the year.

Titan Pharmaceuticals (TTNP) Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Nov 14, 1:01PM CST


Titan Pharmaceuticals EPS and revenue in-line
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 9:38AM CST


Titan Pharmaceuticals Announces Third Quarter 2014 Financial Results
Marketwired - Thu Nov 13, 6:02AM CST
Titan Pharmaceuticals, Inc. (OTCBB: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura(TM) long-term drug delivery technology, today reported financial results for the third quarter ended Sept. 30, 2014.

Titan Pharmaceuticals Appoints Two New Board Members
Marketwired - Tue Nov 11, 6:01AM CST
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) announced today that it has appointed life sciences industry veterans Joseph A. Akers and James McNab Jr. to its board of directors. Mr. Akers, a former Bayer HealthCare executive, and Mr. McNab, chairman and co-founder of Curis, Inc., together bring extensive product development, commercialization, finance and corporate governance experience to Titan.
CRIS: 1.29 (+0.04)

Titan Pharma reports November 14
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 8:12AM CST


Titan Pharmaceuticals Schedules Conference Call to Review Third Quarter 2014 Financial Results
Marketwired - Fri Nov 07, 6:01AM CST
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced that it will host a live conference call at 11 a.m. EST / 8 a.m. PST on Friday, Nov. 14, 2014 to discuss the company's financial results as of Sept. 30, 2014. The call will be hosted by Sunil Bhonsle, president; Kate Glassman Beebe, Ph.D., executive vice president and chief development officer; Brian Crowley, vice president of finance, and Marc Rubin, M.D., executive chairman. Highlights of the third quarter and financial results will be included in a press release to be issued prior to the call.

Genervon ALS drug shows encouraging results
Seeking Alpha - at Seeking Alpha - Mon Oct 20, 7:27AM CDT

BIIB: 340.89 (+5.13), MNOV: 3.04 (unch), CHTP: 6.52 (-0.03), ADMS: 16.10 (+1.45), ACOR: 39.14 (+0.74), BCLI: 3.85 (+0.22), BSX: 13.13 (+0.07), IPXL: 31.32 (+0.26), AVNR: 16.91 (+0.01), ACAD: 30.95 (+0.78), CVTS: (), MRK: 57.46 (+0.25), TEVA: 57.09 (+0.33), PRTA: 20.14 (+1.41), PRAN: 1.74 (-0.02), FOLD: 7.94 (+0.06), CUR: 2.70 (+0.07)

Titan Pharmaceuticals Announces Pricing of Public Offering
Marketwire - Fri Oct 03, 7:37AM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura(TM) long-term delivery technology, today announced the pricing of an underwritten public offering of 21,000,000 units at an offering price of $0.50 per unit, with each unit consisting of one share of common stock and 0.75 of a warrant, each full warrant to purchase one share of common stock at an exercise price of $0.60 per share. Titan expects to receive gross proceeds of $10.5 million from this offering, before deducting underwriting discounts, commissions and other related expenses.

Titan Pharmaceuticals Announces Enrollment Reaches Halfway Mark in Phase 3 Study of Probuphine for Opioid Dependence
Marketwire - Tue Sep 23, 6:00AM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced that patient enrollment in the Phase 3 study of Probuphine(R), the company's investigational subdermal implant for the maintenance treatment of opioid dependence, has reached the halfway mark. Titan's partner, Braeburn Pharmaceuticals, is sponsoring the study and expects it to be fully enrolled before the end of this year, with study completion on schedule by the middle of 2015. The study is designed to support resubmission of the New Drug Application for Probuphine with the U.S. Food and Drug Administration, which is expected later in 2015.

Titan Pharmaceuticals to Present at Rodman & Renshaw 16th Annual Global Investment Conference
Marketwire - Wed Sep 03, 6:01AM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of opioid dependence, Parkinson's Disease, and other serious medical disorders, today announced that Titan President Sunil Bhonsle will present at the Rodman & Renshaw 16th Annual Global Investor Conference at the New York Palace Hotel in New York City on Sept. 10 from 9:35-10 a.m. The presentation will take place in the Kennedy II Salon.

IPOs and Transactions: August 25 - 29
PR Newswire - Tue Sep 02, 12:57PM CDT
Vintage, the regulatory compliance and shareholder communications division of PR Newswire, has released its weekly IPO and Transaction summary.
BNCN: 17.43 (-0.24), ROX: 1.45 (-0.04), GPT: 6.96 (+0.06)

Titan Pharmaceuticals Announces Second Quarter 2014 Financial Results
Marketwire - Wed Aug 13, 6:01AM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of opioid dependence and other serious medical disorders, today reported financial results for the second quarter ended June 30, 2014.

Titan Pharmaceuticals Schedules Conference Call to Review Second Quarter 2014 Financial Results
Marketwire - Thu Aug 07, 6:00AM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced that it will host a live conference call at 10 a.m. PT / 1 p.m. ET on Thursday, Aug. 14, 2014 to discuss the company's financial results as of June 30, 2014. The call will be hosted by Sunil Bhonsle, president; Katherine Glassman-Beebe, Ph.D., executive vice president and chief development officer; Brian Crowley, vice president of finance, and Marc Rubin, M.D., executive chairman. Highlights of the second quarter and financial results will be included in a press release to be issued prior to the call.

Titan Pharmaceuticals Announces First Patient Enrollment in Clinical Study of Probuphine for Opioid Dependence
Marketwire - Mon Jul 21, 6:00AM CDT
Titan Pharmaceuticals, Inc. (OTCBB: TTNP) today announced enrollment of the first patients in the Phase 3 clinical study to support resubmission of the New Drug Application (NDA) for Probuphine(R), the company's investigational subdermal implant for the maintenance treatment of opioid dependence. The study, which is expected to be completed by the middle of 2015, is designed to address key questions posed by the U.S. Food and Drug Administration (FDA) in its complete response letter last year after review of the original NDA. Titan's partner Braeburn Pharmaceuticals is sponsoring the trial and anticipates resubmission of the NDA to the FDA in late 2015.

Highline Research Advisors Initiates on Titan Pharmaceuticals with a Buy Rating
Thomson Reuters ONE - Mon Jul 07, 9:44AM CDT
SAN FRANCISCO - July 7, 2014 -Michael Higgins from Highline Research Advisors, part of Financial Entrepreneur Platform at Merriman Capital, Inc. ("Merriman" , a wholly owned subsidiary of Merriman Holdings, Inc. (OTCQX: MERR), announced today that it has initiated equity research coverage of Titan Pharmaceuticals, Inc. (OTCQB: TTNP) with a Buy rating and a $3.00 price target.

CSE: 2014-0205-Name and Symbol Change-Synergy Acquisition Corp. (QMP)
Marketwire Canada - Wed Feb 12, 10:20AM CST
Synergy Acquisition Corp. has announced a name change to Genius Properties Ltd.
USTR: 42.04 (-0.13), ONCY: 0.49 (unch), NVO: 43.80 (+1.08)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

GIGABYTE Pitches Local AI Agents to Enterprise Buyers

Updated Category News Views 34

Enterprise AI has reached the awkward stage where a slick chatbot demo no longer cuts it. GIGABYTE used its November 13 AI Partner Summit at the Pacific Palms Resort to make a more grounded pitch: companies need hardware and software setups that can put AI agents to work without casually tossing proprietary information into somebody else’s cloud. That is a sensible...

Continue Reading
SEIA's Young Advisors Put Succession Plans to the Test

Updated Category News Views 36

A $166 million average book is not a cute training-program statistic. It says SEIA’s advisors aged 30 to 39 are already carrying serious client responsibility, and that matters because the registered investment advisory business is headed into a succession crunch nobody can solve with a glossy recruiting brochure. You Cannot Hand Off Trust Like a Spare Key Clients may...

Continue Reading
Nevada’s Space Academy Bid Has Assets, Not a Win Yet

Updated Category News Views 5

Desert acreage and a moon-landing backstory make for a handsome pitch, but Nevada is still standing at the starting line. The state has submitted its official response to NASA’s Request for Information for a proposed United States Space Academy, and the new promotional video is meant to show why the Silver State belongs in the conversation. Fair enough. There is real...

Continue Reading
Tessera Delisting Leaves HLSQ in a Tougher Market Ahead

Updated Category News Views 70

November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...

Continue Reading
Neurelis Founder Earns EY's 2026 Top Entrepreneur Honor

Updated Category News Views 20

Some business awards are wallpaper; this one carries real clinical weight. EY US named Craig Chambliss, CEO and co-founder of Neurelis, its Entrepreneur Of The Year 2026 National Overall Award winner. In a sector where plenty of companies talk grandly about changing lives and then vanish into the regulatory fog, the underlying story matters more than the trophy. Neurelis...

Continue Reading
PAG, HOWL and PSNL Deals Face Fresh Shareholder Checks

Updated Category News Views 60

Three proposed takeovers, three very different headaches, and one familiar question that never gets old: are regular shareholders actually receiving the best available deal? On Nov. 20, 2026, investor-rights law firm Halper Sadeh LLC said it was investigating the proposed transactions involving Penske Automotive Group, Werewolf Therapeutics and Personalis for potential...

Continue Reading
AMP Pushes Debt Wall to 2029 With €1.3B Green Notes

Updated Category News Views 83

A Refinancing With Some Actual Breathing Room Metal cans may be boring, but a debt wall arriving in 2028 is not—and Ardagh Metal Packaging has moved that problem down the road. AMP priced €1.3 billion of senior secured floating-rate green notes on November 20, 2026. The proceeds are earmarked to redeem $600 million of senior secured green notes due in 2028 and €450...

Continue Reading
SHEIN's EU Training Push Targets Seller Compliance Gaps

Updated Category News Views 72

Chemicals buried in a cheap handbag or kids' accessory can wreck a marketplace's credibility faster than any glossy campaign can repair it. That is the uncomfortable backdrop to SHEIN and SPEAC's November 19 session on EU chemical-safety rules for marketplace sellers. This was not a fashion trend webinar; it was a practical warning about high-risk substances, regulatory...

Continue Reading
Subsplash Builds a Broader Church Software Stack in 2026

Updated Category News Views 54

Church software has spent too many years behaving like a junk drawer, and Subsplash is plainly trying to replace it with one working system. The company used its November 18 Product Event in Dallas to show off releases from 2026 and preview two additions: Communications, due in December, and Subsplash Intelligence, targeted for early 2027. A Serious Push Beyond the Church...

Continue Reading
E-Rate Risk and Data Center Rules Demand Attention

Updated Category News Views 55

America’s digital plumbing is getting squeezed at both ends: the public connections nobody notices until they fail, and the industrial-scale computing boom everybody suddenly wants built yesterday. Connected Nation’s two bonus podcast episodes from the Broadband Nation Expo in New Orleans put those pressures side by side, and it is a more useful pairing than it may...

Continue Reading

Top 5 Most Recently Viewed Articles

Strategies for Maximizing Your Retirement with $1 Million

Updated Category News Views 148

Planning for a Comfortable Retirement with $1 Million Reaching the milestone of having $1 million saved in your IRA as you near your 70th birthday is a commendable accomplishment. However, to make sure this amount lasts throughout your retirement, which could extend over two decades, careful planning is essential. Effectively managing your retirement funds requires a good...

Continue Reading
Wells Fargo Downgrades SailPoint to Equalweight: What It Means

Updated Category News Views 116

Wells Fargo Downgrades SailPoint Technologies Holdings Wells Fargo has recently revised its stance on SailPoint Technologies Holdings (NYSE: SAIL), changing its investment rating from Overweight to Equalweight. Alongside this rating downgrade, the bank has also lowered its price target for the stock from $17 to $15. This shift indicates a more reserved outlook on the...

Continue Reading
Brunswick Exploration's Promising Lithium Recovery Results

Updated Category News Views 120

Promising Phase 1 Metallurgical Results from Brunswick Exploration Brunswick Exploration Inc. (TSX-V: BRW; OTCQB: BRWXF; Frankfurt: 1XQ) has exciting developments regarding its Mirage Project. The Montreal-based mineral exploration company is charting a significant course in extracting lithium through innovative methodologies. Recent preliminary metallurgical results from...

Continue Reading
Enhancing Bone Health: A New Partnership in Australia

Updated Category News Views 174

The Global Healthy Living Foundation Australia (GHLF Australia) forged a partnership with The Bone Bus back then, aiming to pump up bone health access in rural spots where folks were really struggling. This initiative wasn't just some PR stunt; it targeted real issues surrounding osteoporosis that so many older Australians faced. Rural Access: A Tough Nut to Crack Let’s...

Continue Reading
Kotak Securities Revises Target for Larsen & Toubro, Maintains Sell Rating

Updated Category News Views 176

Kotak Securities slammed the brakes on any bullish sentiment around Larsen & Toubro Ltd. (LT:IN) back in late 2024, despite raising their price target from INR3,150 to INR3,380. Now, this sounds like good news on paper—a bit of upward adjustment—but let’s not kid ourselves here. They slapped a Sell rating on it right alongside that shiny new number. What gives?...

Continue Reading